At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
CLS-AX +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating CLS-AX and Anti-VEGF for Neovascular Age-related Macular Degeneration. Completed, enrolled 27 participants across 11 sites.
Detailed Summary
To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration (AMD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionOct 2022
TodayJul 2026
First PostedNov 12, 2020
Enrollment StartDec 15, 2020
Primary CompletionOct 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.6 years ago
Interventions
CLS-AXdrug
injectable suspension of small molecule tyrosine kinase inhibitor (TKI)
Anti-VEGFdrug
Standard of care therapy used to block vascular endothelial growth factor